Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCRa trial of first-line osimertinib with or without consolidation radiotherapy in oligometastatic EGFR-mutated NSCLC
2021-003305-21Phase 2Terminated
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Progression-free survival. Started Nov 2021; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-003305-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003305-21.